COMPANY PROFILE
| Price and Volume | |
|---|---|
| Recent Price | 45.29 |
| 52 Week High | 47.61 |
| 52 Week Low | 29.96 |
| Avg. Daily Vol. (Mil) | 1.53 |
| Beta (3 year) | 0.74 |
| Share Related Items | |
| Mkt Cap (Mil) | 65,579.92 |
| Shares Out (Mil) | 1,448.00 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 2.60 |
| Annual Dividend | 1.18 |
| Payout Ratio | 42.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.54 |
| Total Debt / Equity | 0.59 |
| Valuation Ratios | |
| Price Earnings | 9.10 |
| Price/Sales | 2.05 |
| Price/Book | 3.38 |
| Price/Cash Flow | 6.90 |
| Per Share Data | |
| Earnings | 4.99 |
| Sales | 22.14 |
| Book Value | 13.39 |
| Cash Flow | 6.53 |
| Business Summary | |
|---|---|
| The company discovers, develops, manufactures and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. | |
| General Information | |
| 15 Stanhope Gate
London, W1K 1LN |
|
| 0.99999999965843 | |
| www.astrazeneca.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 66100 | |
| CEO: David R. Brennan | |
| Short Interest | |
| Current Month (Mil) | 5.62 |
| Previous Month (Mil) | 6.24 |
| Short Interest Ratio (Days) | 3.80 |
| Management Effectiveness | |
| Return on Equity | 37.20 |
| Return on Assets | 13.90 |
| Return on Investments | 24.10 |
| Profitability | |
| Gross Margin | 87.60 |
| EBIT Margin | 36.30 |
| Profit Margin | 22.50 |